Swedish Body Certifies Bend Research for EU GMP Compliance

By Dan Stanton

- Last updated on GMT

Related tags: Food and drug administration, Pharmacology, European union

Swedish MPA certify Bend Research' manufacturing facilities
Swedish MPA certify Bend Research' manufacturing facilities
Bend Research says collaboration between the Swedish MPA and the US FDA was the reasoning in pursuing GMP from the European body.

The Oregon based research and manufacturing company has received an EU Certificate of GMP (good manufacturing practice) after voluntary inspections at its facilities by the Swedish Medical Products Agency (MPA).

The Swedish body is one of only a few European agencies which regularly conducts inspections outside Europe. The approval will allow Bend to increase its services to clients who need European compliance in the research and manufacture of oral and inhaled drug-product intermediates, as well as drug products such as tablets and capsules.

Debra Katter, Vice President of Corporate Quality, explained that Bend chose the MPA because it is covered under a Confidentiality Agreement​ which is part of the FDA’s (US Food and Drug Administration) Initiative for Global Product and Safety​.

The two regulatory bodies “entered into the Confidentiality Agreement,”​ Katter told Outsourcing-Pharma.com, allowing the sharing of “information that would not be available for public disclosure under U.S. laws and regulations.”

The certification covers both of Bend’s manufacturing Oregon facilities in manufacturing and testing bulk drug products and drug-product intermediates. The GMP extends to the laboratories associated with the plants.

In providing a service that will appeal to its clients on a global scale, Katter added that: The Swedish MPA inspection was very informative and assisted us greatly in our efforts.”

'Around the Bend'

Bend has inked deals with several big pharma companies including Eli Lilly​ and Merck​ over access to its spray-dried dispersion technology and thus European compliance is the latest in proactive achievements as it attempts to increase its services to clients.

A series of upgrades and new technologies were implemented last year, including a new 18mm hot melt extruder​ which led the way to offering hot melt extrusion capability. This is on top of spray-drying, which also saw an expansion last August​ when a new spray-drying facility let the company work with high-potency ingredients.

Related news

Show more

Related products

show more

How clinical trial software can optimize trials

How clinical trial software can optimize trials

Formedix | 20-Jun-2022 | Technical / White Paper

This article explains the different types of clinical trial software available, and how it can be used to optimize the end to end clinical trials design...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Related suppliers

Follow us


View more